Quest Diagnostics (DGX) Tops Q4 EPS by 6c, Beats on Revenue; Offers FY26 Guidance

Quest Diagnostics (NYSE: DGX) reported Q4 EPS of $2.42, $0.06 better than the analyst estimate of $2.36. Revenue for the quarter came in at $2.81 billion versus the consensus estimate of $2.75 billion.

GUIDANCE:

Quest Diagnostics sees FY2026 EPS of $10.50-$10.70, versus the consensus of $10.42. Quest Diagnostics sees FY2026 revenue of $11.7-11.82 billion, versus the consensus of $11.36 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• NASA selects 3 companies for 4 lunar missions worth $590M
• NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
• Citi Upgrades Page Industries Ltd. (PAG:IN) to Buy, Opens Positive 90-Day Catalyst Watch